Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that members of its management team will participate in two investor conferences in August and September 2026. President and Chief Executive Officer Dr. Seth Lederman will take part in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Aug. 11 from 1:30 p.m. to 1:55 p.m. ET. The company also said Lederman will participate in one-on-one meetings at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Sept. 16. These events provide Tonix an opportunity to discuss its business and engage with the investment community.
The announcement comes at a pivotal time for Tonix as it continues to commercialize TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), its recently approved flagship medicine and the first new treatment for fibromyalgia in more than 15 years. With a fully integrated commercial infrastructure, the company is also supporting its acute migraine products, Zembrace® SymTouch® and Tosymra®. Beyond commercial products, Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder, conditions that represent significant unmet medical needs.
The company's CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare genetic disorder. In the immunology space, Tonix is advancing monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These pipeline candidates highlight Tonix's strategic focus on areas where treatment options are limited or inadequate.
Investor conferences such as these are critical for biotech companies to articulate their value proposition, update stakeholders on clinical progress, and gauge investor sentiment. For Tonix, the fireside chat and one-on-one meetings offer a platform to highlight the commercial launch of TONMYA and the potential of its pipeline. The company's participation also signals confidence in its strategic direction and ongoing efforts to address high-unmet medical needs.
According to the company, TONMYA's approval represents a significant milestone for the fibromyalgia community, offering a new therapeutic option for patients who have had limited choices for over a decade. The ongoing Phase 2 trials for major depressive disorder and acute stress disorder could expand TONMYA's label, potentially broadening its market opportunity. Similarly, progress in the immunology pipeline, particularly TNX-1500 for kidney transplant rejection, addresses a critical need in transplantation medicine.
Tonix's management team will be available to discuss these developments and answer questions during the conferences. Investors and industry observers will be watching closely for any updates on clinical trial timelines, regulatory interactions, and commercial performance. The company's ability to communicate its strategy and milestones effectively at these events could influence investor confidence and market perception.
For more information about Tonix Pharmaceuticals and its pipeline, visit the company's newsroom at https://ibn.fm/TNXP. Details of the full press release can be found at https://ibn.fm/DKFAC.
